The following is a list of the top 100 prescribed medicines by US National Sales in Q1 2013. Figures include sales through both retail and hospital channels, listed by drug name and units sold in the United States.
| Rank |
Drug |
Units (000) |
|
|
| 1 |
budesonide
Generic |
12,470 |
0.81% |
Stats |
| 2 |
acetaminophen/hydrocodone
Generic |
10,024 |
-2.92% |
Stats |
3 ( ) |
omeprazole
Generic |
8,048 |
 |
Stats |
4 ( 1) |
ProAir HFA
Teva Pharmaceuticals |
6,765 |
-11.64% |
Stats |
| 5 (1) |
Nexium
AstraZeneca Pharmaceuticals |
6,667 |
-2.47% |
Stats |
| 6 (1) |
Cymbalta
Eli Lilly and Company |
6,502 |
-2.09% |
Stats |
7 ( 1) |
atorvastatin
Generic |
6,388 |
4.70% |
Stats |
| 8 (1) |
ONE TOUCH ULTRA
|
6,110 |
-0.70% |
Stats |
| 9 |
Ventolin HFA
GlaxoSmithKline |
6,063 |
1.27% |
Stats |
| 10 |
Advair Diskus
GlaxoSmithKline |
5,959 |
1.81% |
Stats |
| 11 (5) |
Lantus
Sanofi-Aventis |
5,790 |
-9.19% |
Stats |
| 12 (1) |
Lantus Solostar
Sanofi-Aventis |
4,928 |
5.57% |
Stats |
| 13 |
enoxaparin
Generic |
4,311 |
-0.90% |
Stats |
| 14 (9) |
Tamiflu
Roche Pharmaceuticals |
4,205 |
67.13% |
Stats |
| 15 (1) |
Crestor
AstraZeneca Pharmaceuticals |
4,106 |
-2.93% |
Stats |
| 16 (4) |
fentanyl
Generic |
4,078 |
-6.62% |
Stats |
| 17 (2) |
Spiriva
Boehringer Ingelheim Pharmaceuticals, Inc |
3,609 |
-1.50% |
Stats |
| 18 (1) |
Levemir
Novo Nordisk Inc. |
3,348 |
4.92% |
Stats |
| 19 (3) |
Novolog
Novo Nordisk Inc. |
3,040 |
-10.03% |
Stats |
| 20 (2) |
NovoLog FlexPen
Novo Nordisk Inc. |
2,979 |
-1.52% |
Stats |
| 21 (4) |
metoprolol
Generic |
2,854 |
16.39% |
Stats |
| 22 (2) |
Humalog
Eli Lilly and Company |
2,708 |
2.85% |
Stats |
| 23 (1) |
Nasonex
Merck & Co., Inc. |
2,655 |
4.32% |
Stats |
| 24 |
Synthroid
Abbott Laboratories |
2,484 |
1.22% |
Stats |
| 25 (4) |
Abilify
Otsuka Pharmaceutical Co. |
2,477 |
-5.89% |
Stats |
| 26 |
Januvia
Merck & Co., Inc. |
2,378 |
0.38% |
Stats |
| 27 |
Symbicort
AstraZeneca Pharmaceuticals |
2,210 |
-4.45% |
Stats |
| 28 (1) |
Lyrica
Pfizer Inc |
2,074 |
0.29% |
Stats |
| 29 (1) |
Suboxone
Reckitt Benckiser Pharmaceuticals Inc. |
2,066 |
0.58% |
Stats |
| 30 (2) |
Namenda
Forest Pharmaceuticals, Inc |
2,011 |
-3.55% |
Stats |
| 31 |
Zetia
Merck & Co., Inc. |
1,995 |
0.86% |
Stats |
| 32 (1) |
Diovan
Novartis Corporation |
1,923 |
1.75% |
Stats |
| 33 (1) |
Flovent HFA
GlaxoSmithKline |
1,907 |
-2.80% |
Stats |
| 34 |
Combivent
Boehringer Ingelheim Pharmaceuticals, Inc |
1,765 |
-1.89% |
Stats |
| 35 (16) |
AndroGel
Abbott Laboratories |
1,687 |
-40.11% |
Stats |
| 36 (1) |
Lidoderm
Endo Pharmaceuticals |
1,650 |
-5.23% |
Stats |
| 37 (5) |
fenofibrate
Generic |
1,618 |
26.11% |
Stats |
| 38 (1) |
Remicade
Centocor Ortho Biotech, Inc |
1,590 |
2.51% |
Stats |
| 39 (3) |
Lovaza
GlaxoSmithKline |
1,570 |
-4.33% |
Stats |
| 40 (1) |
Benicar
Daiichi Sankyo |
1,499 |
-0.27% |
Stats |
| 41 (1) |
Dexilant
Takeda Pharmaceuticals North America, Inc |
1,495 |
0.13% |
Stats |
| 42 (4) |
Restasis
Allergan, Inc |
1,490 |
-3.62% |
Stats |
| 43 |
OxyContin
|
1,176 |
-5.47% |
Stats |
| 44 () |
Benicar HCT
Daiichi Sankyo |
1,155 |
|
Stats |
| 45 () |
Humalog KwikPen
|
1,137 |
|
Stats |
| 46 (1) |
VESIcare
Astellas Pharma US |
1,126 |
6.03% |
Stats |
| 47 (3) |
Vytorin
Merck & Co., Inc. |
1,069 |
-4.30% |
Stats |
| 48 (2) |
Celebrex
Pfizer Inc |
1,009 |
-4.90% |
Stats |
| 49 (1) |
Pradaxa
Boehringer Ingelheim Pharmaceuticals, Inc |
983 |
-0.20% |
Stats |
| 50 (1) |
Janumet
Merck & Co., Inc. |
971 |
-0.61% |
Stats |
| 51 (4) |
Enbrel
Amgen Inc. |
969 |
-6.83% |
Stats |
| 52 (2) |
Niaspan
Abbott Laboratories |
902 |
-4.25% |
Stats |
| 53 (2) |
Evista
Eli Lilly and Company |
878 |
-4.25% |
Stats |
| 54 () |
doxycycline
Generic |
849 |
|
Stats |
| 55 () |
hydrochlorothiazide/valsartan
Generic |
839 |
|
Stats |
| 56 (1) |
Cialis
Eli Lilly and Company |
836 |
2.20% |
Stats |
| 57 (5) |
methylphenidate
Generic |
826 |
-1.90% |
Stats |
| 58 (4) |
Vyvanse
Shire US Inc |
814 |
-2.75% |
Stats |
| 59 (3) |
amphetamine/dextroamphetamine
Generic |
764 |
-0.13% |
Stats |
| 60 (3) |
Aciphex
Eisai Corporation |
652 |
-10.56% |
Stats |
| 61 (3) |
Humira
Abbott Laboratories |
631 |
-5.68% |
Stats |
| 62 |
Victoza
Novo Nordisk Inc. |
607 |
9.76% |
Stats |
| 63 (3) |
Epogen
Amgen Inc. |
590 |
-2.64% |
Stats |
| 64 (5) |
Rebif
|
562 |
-8.17% |
Stats |
| 65 (2) |
Rituxan
Genentech, Inc |
560 |
1.82% |
Stats |
| 66 (5) |
Truvada
Gilead Sciences, Inc. |
548 |
-8.51% |
Stats |
| 67 (1) |
Atripla
Gilead Sciences, Inc. |
479 |
-0.83% |
Stats |
| 68 (1) |
Avastin
Genentech, Inc |
462 |
|
Stats |
| 69 (5) |
Viagra
Pfizer Inc |
442 |
-12.48% |
Stats |
| 70 (2) |
Seroquel XR
AstraZeneca Pharmaceuticals |
406 |
-4.69% |
Stats |
| 71 (2) |
modafinil
Generic |
371 |
-6.78% |
Stats |
| 72 (2) |
Renvela
Genzyme Corporation |
354 |
-1.39% |
Stats |
| 73 (2) |
Lunesta
Sunovion Pharmaceuticals Inc. |
336 |
-2.61% |
Stats |
| 74 (1) |
Neulasta
Amgen Inc. |
329 |
4.11% |
Stats |
| 75 (3) |
Adderall XR
Shire US Inc |
326 |
-3.26% |
Stats |
| 76 (3) |
Orencia
Bristol-Myers Squibb Company |
325 |
-0.91% |
Stats |
| 77 (3) |
Sensipar
Amgen Inc. |
309 |
-4.92% |
Stats |
| 78 (2) |
Focalin XR
Novartis Corporation |
291 |
-5.21% |
Stats |
| 79 (1) |
Xolair
|
276 |
-0.72% |
Stats |
| 80 (3) |
Procrit
Janssen Pharmaceuticals, Inc |
270 |
-3.23% |
Stats |
| 81 (1) |
Isentress
Merck & Co., Inc. |
269 |
-0.37% |
Stats |
| 82 (3) |
Reyataz
Bristol-Myers Squibb Company |
262 |
-5.42% |
Stats |
| 83 (2) |
Aranesp
Amgen Inc. |
247 |
-4.63% |
Stats |
| 84 (1) |
Prezista
Janssen Pharmaceuticals, Inc |
245 |
-0.41% |
Stats |
| 85 (1) |
Lucentis
Genentech, Inc |
242 |
6.14% |
Stats |
| 86 (3) |
Synagis
MedImmune, Inc |
238 |
44.24% |
Stats |
| 87 (5) |
Copaxone
Teva Pharmaceuticals |
229 |
-8.03% |
Stats |
| 88 (2) |
Alimta
Eli Lilly and Company |
179 |
-9.60% |
Stats |
| 89 (1) |
Herceptin
Genentech, Inc |
167 |
1.83% |
Stats |
| 90 (2) |
Neupogen
Amgen Inc. |
163 |
-4.12% |
Stats |
| 91 (4) |
Prevnar 13
Wyeth |
154 |
-13.97% |
Stats |
| 92 (1) |
Zyvox
Pfizer Inc |
142 |
11.81% |
Stats |
| 93 (1) |
Xgeva
Amgen Inc. |
122 |
5.17% |
Stats |
| 94 (1) |
Avonex
Biogen Idec |
97 |
-13.39% |
Stats |
| 95 (1) |
Gleevec
Novartis Corporation |
82 |
-5.75% |
Stats |
| 96 (1) |
Xeloda
Roche Pharmaceuticals |
59 |
-9.23% |
Stats |
| 97 |
Betaseron
Bayer Healthcare Pharmaceuticals |
57 |
-6.56% |
Stats |
| 98 |
Gilenya
Novartis Corporation |
56 |
-1.75% |
Stats |
| 99 |
Stelara
|
24 |
4.35% |
Stats |
| 100 |
Incivek
Vertex Pharmaceuticals |
14 |
-12.50% |
Stats |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
)
1)
1)